Neuphoria Therapeutics, Inc. (NEUP)
3.06
-0.30
(-8.93%)
USD |
NASDAQ |
Oct 29, 16:00
3.10
+0.04
(+1.31%)
Pre-Market: 08:09
Neuphoria Therapeutics Gross Profit Margin (Quarterly) : 85.89% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 85.89% |
| March 31, 2026 | |
| December 31, 2025 |
| Date | Value |
|---|---|
| September 30, 2025 | |
| March 31, 2025 | 98.90% |
| December 31, 2024 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
| Anika Therapeutics, Inc. | 65.15% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
| Imunon, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -55.03% |
| Return on Assets | -42.52% |
| Return on Invested Capital | -54.85% |
| Profit Margin (Quarterly) | -417.7% |
| Operating Margin (Quarterly) | -13.96% |
| Return on Net Operating Assets | -108.1% |